1. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
- Author
-
Hoffmann, Markus, Kleine-Weber, Hannah, Schroeder, Simon, Krüger, Nadine, Herrler, Tanja, Erichsen, Sandra, Schiergens, Tobias S., Herrler, Georg, Wu, Nai-Huei, Nitsche, Andreas, Müller, Marcel A., Drosten, Christian, and Pöhlmann, Stefan
- Subjects
- *
COVID-19 , *PROTEASE inhibitors , *VIRAL transmission , *SARS virus - Abstract
The recent emergence of the novel, pathogenic SARS-coronavirus 2 (SARS-CoV-2) in China and its rapid national and international spread pose a global health emergency. Cell entry of coronaviruses depends on binding of the viral spike (S) proteins to cellular receptors and on S protein priming by host cell proteases. Unravelling which cellular factors are used by SARS-CoV-2 for entry might provide insights into viral transmission and reveal therapeutic targets. Here, we demonstrate that SARS-CoV-2 uses the SARS-CoV receptor ACE2 for entry and the serine protease TMPRSS2 for S protein priming. A TMPRSS2 inhibitor approved for clinical use blocked entry and might constitute a treatment option. Finally, we show that the sera from convalescent SARS patients cross-neutralized SARS-2-S-driven entry. Our results reveal important commonalities between SARS-CoV-2 and SARS-CoV infection and identify a potential target for antiviral intervention. • SARS-CoV-2 uses the SARS-CoV receptor ACE2 for host cell entry • The spike protein of SARS-CoV-2 is primed by TMPRSS2 • Antibodies against SARS-CoV spike may offer some protection against SARS-CoV-2 The emerging SARS-coronavirus 2 (SARS-CoV-2) threatens public health. Hoffmann and coworkers show that SARS-CoV-2 infection depends on the host cell factors ACE2 and TMPRSS2 and can be blocked by a clinically proven protease inhibitor. These findings might help to establish options for prevention and treatment. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF